EraCal Therapeutics Ltd. is a Swiss biotech company committed to cutting-edge science and medicine.
Drug Discovery Platform
EraCal’s platform enables unbiased and large-scale in vivo drug discovery in zebrafish larvae. The journal Science Advances published part of EraCal’s translational proof of concept. Such phenotypic strategies are capable of identifying novel mechanisms of actions and, consequently, are a prime choice to discover first-in-class drugs.
Today millions of people are obese. At the individual level, obesity reduces life expectancy by 3-4 years causing complications such as type 2 diabetes, psychosocial disorders, cancers among many others. Therapeutic options for weight loss exist in the form of lifestyle therapy, weight-lowering drugs and/or bariatric surgeries depending on the disease severity and complications. Unfortunately, all offer a poor benefit/risk ratio to reduce obesity and to prevent the onset of obesity-associated complications. EraCal’s lead molecule, Era-107, is an oral appetite suppressor with a superior efficacy and safety profile compared to the anti-obesity drug lorcaserin, as has been demonstrated in three vertebrate animal models.